-
公开(公告)号:US20210198361A1
公开(公告)日:2021-07-01
申请号:US17058794
申请日:2019-05-30
发明人: Hiroyoshi NISHIKAWA , Yosuke TOGASHI , Yukiya OHYAMA , Takao YOSHIDA , Kazuhiko TAKEDA , Kenichi KODA , Atsushi HONDA , Atsushi OYAGI , Toru KAKINUMA , Masayuki MURATA
摘要: The object of the present invention is to provide a method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on those.
The present invention can provide agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing the evaluation items consisting of combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8+ T cells in tumor tissue or blood.-
公开(公告)号:US20220283167A1
公开(公告)日:2022-09-08
申请号:US17632423
申请日:2020-08-04
发明人: Hiroyoshi NISHIKAWA , Yukiya OHYAMA , Atsushi HONDA , Atsushi OYAGI , Toru KAKINUMA , Masayuki MURATA
IPC分类号: G01N33/574
摘要: A method for identifying a patient with malignant tumor which can be expected to benefit more from an immune checkpoint inhibitor, and agent for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, being prescribed based thereon, comprising use of a combination of two sets of evaluation items and specific condition defined by each of combination thereof.
-